KC
CRSP icon

Knuff & Co’s CRISPR Therapeutics CRSP Stock Holding History

Knuff & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$7K – 134
2022
Q3 		$7K Hold
100
– – ﹤0.01% 127
2022
Q2 		$6K Hold
100
– – ﹤0.01% 131
2022
Q1 		$6K Hold
100
– – ﹤0.01% 135
2021
Q4 		$8K Hold
100
– – ﹤0.01% 146
2021
Q3 		$11K Hold
100
– – ﹤0.01% 149
2021
Q2 		$16K Hold
100
– – 0.01% 148
2021
Q1 		$12K Hold
100
– – 0.01% 144
2020
Q4 		$15K Hold
100
– – 0.01% 149
2020
Q3 		$8K Buy
+100
New +$8.87K ﹤0.01% 169

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Knuff & Co's CRSP Position: Q4 2022 in Review

Knuff & Co sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 100 shares — an estimated $7K sold.

Knuff & Co first reported a position in CRSP in Q3 2020 and held it in 9 quarters. The position peaked at $16K in Q2 2021. 396 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

  • Knuff & Co reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Knuff & Co sold 100 CRISPR Therapeutics shares in Q4 2022, an estimated $7K.
  • Knuff & Co first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 9 quarters.
  • Knuff & Co's CRISPR Therapeutics position peaked at $16K in Q2 2021.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Knuff & Co's 13F filing for Q4 2022, filed 9 Feb 2023.